Thyroid cancer: no survival benefit for total thyroidectomy/RAI in low-risk elders

  • Zambeli-Ljepović A & al.
  • J Surg Res
  • 8 Jun 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Total thyroidectomy and radioactive iodine (RAI) are not associated with improved disease-specific survival (DSS) in patients aged ≥66 years with T1N0M0 papillary thyroid cancer (PTC).

Why this matters

  • Less aggressive treatment may reduce morbidity and improve QoL, while maintaining an excellent prognosis.

Key results

  • 65.4% of patients underwent total thyroidectomy, 29.0% underwent lobectomy, and 5.6% underwent lobectomy followed by complete thyroidectomy.
  • 33.4% of patients received postoperative RAI.
  • Tumor size of 1.1-2 cm was associated with extent of surgery (OR, 3.96 [P<.01 for completion thyroidectomy or total and rai>
  • Multifocality was associated with extent of surgery (OR, 3.51 [P<.01 for completion thyroidectomy or total and rai>
  • Preoperative PTC diagnosis was associated with extent of surgery (OR, 0.52 [P<.01 for completion thyroidectomy or total and rai>
  • Extent of surgery (aHR, 0.50 for completion thyroidectomy; aHR, 1.08 for total thyroidectomy; P=.75) and RAI (aHR, 1.41; P=.42) were not associated with DSS in adjusted analysis.

Study design

  • 3214 patients aged ≥66 years with clinical T1N0M0 PTC were analyzed for treatment modality and associated DSS outcomes.
  • Funding: NIH.

Limitations

  • Retrospective study of large database.